Anticancer Peptide Injection Protocols for Scar-Minimized BCC Treatment
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Current treatments for non-melanoma skin cancer, particularly basal cell carcinoma (BCC), such as surgery and non-invasive therapies, are associated with scarring and safety concerns, necessitating the development of safe and effective non-invasive methods.
Innovation Solution
Administration of an anti-cancer peptide (Peptide A with the sequence KKWWKKWDipK-NH2) through intradermal injection, utilizing partitioned and radial injection protocols to treat BCC, minimizing treatment-related adverse events.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Reliability
If surgery is used to treat BCC, then the cancer is effectively removed, but scarring occurs at the treatment area
Solution Approach 1:
The patent replaces mechanical surgical excision with a chemical/biological mechanism using an oncolytic peptide that selectively destroys cancer cells through molecular interaction rather than physical removal, thereby eliminating the need for incisions and sutures that cause scarring
2Object-affected harmful factors
If Mohs micrographic surgery is used to reduce scarring, then scar formation is minimized, but the procedure becomes complex and requires specialized training
Solution Approach 1:
The patent replaces complex mechanical surgical procedures with a simple intradermal injection of an oncolytic peptide, eliminating the need for specialized surgical training and complex procedural steps while achieving comparable or superior cosmetic outcomes
Solution Approach 2:
The treatment is divided into simple, discrete intradermal injection steps that can be easily performed without specialized surgical training, making the procedure accessible to broader medical practitioners
3Ease of operation
If topical and intradermal therapies are used to treat BCC, then non-invasive treatment is achieved, but toxicity and safety concerns arise
Solution Approach 1:
The oncolytic peptide exhibits selective toxicity through local quality - it specifically targets and destroys cancer cells while leaving healthy cells unaffected, achieving non-invasive treatment without systemic toxicity by acting only at the injection site
Solution Approach 2:
The patent converts the potential harm of peptide toxicity into a benefit by designing a peptide that selectively targets cancer cells, transforming what could be a toxic side effect into a therapeutic mechanism that spares healthy tissue
Data Source
AI summary
The present disclosure is based on the development of improved clinical protocols for administering an anti-cancer peptide having the sequence of SEQ ID NO: 1, or a pharmaceutically acceptable salt thereof (“Peptide A”), to a subject (e.g., for the treatment of a skin cancer, such as basal cell carcinoma (BCC)). Methods provided herein allow for the safe and effective treatment of skin cancers, including BCC, in a minimally invasive manner. In certain embodiments, methods provided herein allow for administration of Peptide A to a skin cancer lesion (e.g., BCC lesion) on a subject with no significant treatment-related adverse events (TRAEs), e.g., TRAEs such as burning and/or pain at the injection site.